458.55 -2.40 (-0.52%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
453.0
Today’s High
461.5
52 Week Low
378.4
52 Week High
607.5
456.50 -3.80 (-0.83%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
Price Range
Today’s Low
453.05
Today’s High
461.7
52 Week Low
378
52 Week High
608
Key Metrics
- Market Cap (In Cr) 4261.92
- Beta 0.97
- Div. Yield (%) 0
- P/B 4.11
- TTM P/E 23.19
- Peg Ratio 1.41
- Sector P/E 27.15
- D/E 0.53
- Open Price 458.1
- Prev Close 460.95
Analysis
Price Analysis
-
1 Week2.08%
-
3 Months6.13%
-
6 Month8.04%
-
YTD-15.53%
-
1 Year-11.89%
Risk Meter
- 32% Low risk
- 32% Moderate risk
- 32% Balanced Risk
- 32% High risk
- 32% Extreme risk
Recos
3 Analysts
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- Strong Sell
- 0
- Sell
- 0
- Hold
- 2
- Buy
- 1
- Strong Buy
- 0
Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2022
- Total Revenue
- 2488.65
- Selling/ General/ Admin Expenses Total
- 177.01
- Depreciation/ Amortization
- 50.05
- Other Operating Expenses Total
- 7.26
- Total Operating Expense
- 2206.1
- Operating Income
- 282.55
- Net Income Before Taxes
- 269.96
- Net Income
- 205.04
- Diluted Normalized EPS
- 22.14
- Period
- 2022
- Total Assets
- 2207.96
- Total Liabilities
- 1171.6
- Total Equity
- 1036.36
- Tangible Book Valueper Share Common Eq
- 111.9
- Period
- 2022
- Cashfrom Operating Activities
- 69.64
- Cashfrom Investing Activities
- -148.86
- Cashfrom Financing Activities
- 92.03
- Net Changein Cash
- 12.8
- Period
- 2021
- Total Revenue
- 2154.78
- Selling/ General/ Admin Expenses Total
- 165.73
- Depreciation/ Amortization
- 49.88
- Other Operating Expenses Total
- 4.7
- Total Operating Expense
- 1767.33
- Operating Income
- 387.45
- Net Income Before Taxes
- 369.01
- Net Income
- 280.41
- Diluted Normalized EPS
- 30.07
- Period
- 2021
- Total Assets
- 1766.01
- Total Liabilities
- 852.59
- Total Equity
- 913.42
- Tangible Book Valueper Share Common Eq
- 97.98
- Period
- 2021
- Cashfrom Operating Activities
- 154.95
- Cashfrom Investing Activities
- -71.78
- Cashfrom Financing Activities
- -81.13
- Net Changein Cash
- 2.04
- Period
- 2020
- Total Revenue
- 1806.09
- Selling/ General/ Admin Expenses Total
- 144.01
- Depreciation/ Amortization
- 48.75
- Other Operating Expenses Total
- 3.03
- Total Operating Expense
- 1589.33
- Operating Income
- 216.76
- Net Income Before Taxes
- 185.29
- Net Income
- 141.4
- Diluted Normalized EPS
- 14.81
- Period
- 2020
- Total Assets
- 1576.5
- Total Liabilities
- 924.01
- Total Equity
- 652.49
- Tangible Book Valueper Share Common Eq
- 69.85
- Period
- 2020
- Cashfrom Operating Activities
- 250.74
- Cashfrom Investing Activities
- -33.21
- Cashfrom Financing Activities
- -215.41
- Net Changein Cash
- 2.13
- Period
- 2019
- Total Revenue
- 1560.94
- Selling/ General/ Admin Expenses Total
- 109.43
- Depreciation/ Amortization
- 42.56
- Other Operating Expenses Total
- 2.86
- Total Operating Expense
- 1392.59
- Operating Income
- 168.35
- Net Income Before Taxes
- 131.02
- Net Income
- 89.75
- Diluted Normalized EPS
- 9.24
- Period
- 2019
- Total Assets
- 1455.49
- Total Liabilities
- 912.04
- Total Equity
- 543.45
- Tangible Book Valueper Share Common Eq
- 57.3
- Period
- 2019
- Cashfrom Operating Activities
- 143.09
- Cashfrom Investing Activities
- -61.67
- Cashfrom Financing Activities
- -80.07
- Net Changein Cash
- 1.35
- Period
- 2018
- Total Revenue
- 1262.57
- Selling/ General/ Admin Expenses Total
- 102.43
- Depreciation/ Amortization
- 40.06
- Other Operating Expenses Total
- 2.64
- Total Operating Expense
- 1100.76
- Operating Income
- 161.81
- Net Income Before Taxes
- 124.5
- Net Income
- 82.31
- Diluted Normalized EPS
- 8.73
- Period
- 2018
- Total Assets
- 1389.41
- Total Liabilities
- 933.98
- Total Equity
- 455.43
- Tangible Book Valueper Share Common Eq
- 47.8
- Period
- 2018
- Cashfrom Operating Activities
- 69.77
- Cashfrom Investing Activities
- -73.54
- Cashfrom Financing Activities
- 3.92
- Net Changein Cash
- 0.15
- Period
- 2017
- Total Revenue
- 1288.08
- Selling/ General/ Admin Expenses Total
- 92.14
- Depreciation/ Amortization
- 38.46
- Other Operating Expenses Total
- 2.2
- Total Operating Expense
- 1134.13
- Operating Income
- 153.95
- Net Income Before Taxes
- 116.01
- Net Income
- 81.8
- Diluted Normalized EPS
- 8.42
- Period
- 2017
- Total Assets
- 1191.04
- Total Liabilities
- 790.9
- Total Equity
- 400.13
- Tangible Book Valueper Share Common Eq
- 41.29
- Period
- 2017
- Cashfrom Operating Activities
- 174.75
- Cashfrom Investing Activities
- -106.98
- Cashfrom Financing Activities
- -68.23
- Net Changein Cash
- -0.45
- Period
- 2022-09-30
- Total Revenue
- 687.72
- Selling/ General/ Admin Expenses Total
- 22.05
- Depreciation/ Amortization
- 12.66
- Other Operating Expenses Total
- 110.25
- Total Operating Expense
- 626.1
- Operating Income
- 61.62
- Net Income Before Taxes
- 53.19
- Net Income
- 38.74
- Diluted Normalized EPS
- 4.18
- Period
- 2022-09-30
- Total Assets
- 2268.96
- Total Liabilities
- 1159.05
- Total Equity
- 1109.91
- Tangible Book Valueper Share Common Eq
- 119.81
- Period
- 2022-09-30
- Cashfrom Operating Activities
- 36.01
- Cashfrom Investing Activities
- -78.8
- Cashfrom Financing Activities
- 35
- Net Changein Cash
- -7.79
- Period
- 2022-06-30
- Total Revenue
- 621.96
- Selling/ General/ Admin Expenses Total
- 20.82
- Depreciation/ Amortization
- 12.54
- Other Operating Expenses Total
- 105.07
- Total Operating Expense
- 567.37
- Operating Income
- 54.59
- Net Income Before Taxes
- 48.03
- Net Income
- 34.79
- Diluted Normalized EPS
- 3.76
- Period
- 2022-06-30
- Period
- 2022-06-30
- Period
- 2022-03-31
- Total Revenue
- 694.27
- Selling/ General/ Admin Expenses Total
- 21.53
- Depreciation/ Amortization
- 12.55
- Other Operating Expenses Total
- 109.11
- Total Operating Expense
- 620.82
- Operating Income
- 73.45
- Net Income Before Taxes
- 70.5
- Net Income
- 55.34
- Diluted Normalized EPS
- 5.98
- Period
- 2022-03-31
- Total Assets
- 2207.96
- Total Liabilities
- 1171.6
- Total Equity
- 1036.36
- Tangible Book Valueper Share Common Eq
- 111.9
- Period
- 2022-03-31
- Cashfrom Operating Activities
- 69.64
- Cashfrom Investing Activities
- -148.86
- Cashfrom Financing Activities
- 92.03
- Net Changein Cash
- 12.8
- Period
- 2021-12-31
- Total Revenue
- 634.8
- Selling/ General/ Admin Expenses Total
- 20.91
- Depreciation/ Amortization
- 12.6
- Other Operating Expenses Total
- 104.46
- Total Operating Expense
- 557.4
- Operating Income
- 77.4
- Net Income Before Taxes
- 78.69
- Net Income
- 58.29
- Diluted Normalized EPS
- 6.29
- Period
- 2021-12-31
- Period
- 2021-12-31
- Period
- 2021-09-30
- Total Revenue
- 579.62
- Selling/ General/ Admin Expenses Total
- 20.6
- Depreciation/ Amortization
- 12.48
- Other Operating Expenses Total
- 89.78
- Total Operating Expense
- 518.36
- Operating Income
- 61.26
- Net Income Before Taxes
- 56.08
- Net Income
- 42.59
- Diluted Normalized EPS
- 4.6
- Period
- 2021-09-30
- Total Assets
- 1891.01
- Total Liabilities
- 959.71
- Total Equity
- 931.3
- Tangible Book Valueper Share Common Eq
- 100.55
- Period
- 2021-09-30
- Cashfrom Operating Activities
- 35.66
- Cashfrom Investing Activities
- -74.83
- Cashfrom Financing Activities
- 36.08
- Net Changein Cash
- -3.09
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Technical
Moving Average
SMA
- 5 Day451.98
- 10 Day451.65
- 20 Day457.34
- 50 Day462.34
- 100 Day450.43
- 300 Day449.01
Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- FDC
- 284.15
- -2.15
- -0.75
- 323.15
- 229.15
- 4735.07
- Hikal
- 384.85
- 33.8
- 9.63
- 595
- 215.65
- 4297.03
- Aarti Drugs
- 458.55
- -2.4
- -0.52
- 607.5
- 378.4
- 4261.91
- Indoco Remedies
- 397.6
- -0.05
- -0.01
- 458.26
- 307.95
- 3621.97
- Advanced Enzyme Technologies
- 315.8
- 0.05
- 0.02
- 358.55
- 257
- 3434.62
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- FDC
- 22.34
- 2.46
- 14.45
- 17.27
- Hikal
- 26.78
- 4.02
- 13.92
- 6.93
- Aarti Drugs
- 20.79
- 4.11
- 24.33
- 8.61
- Indoco Remedies
- 23.18
- 4
- 8.71
- 5.26
- Advanced Enzyme Technologies
- 28.94
- 3.13
- 15.57
- 26.97
Shareholding
- Category
- Percentage
- No. of shares
- Promoter & Promoter Group Shareholding
- 59.77%
- 55,346,809
- Prakash Moreshwar Patil
- 9.21%
- 8,531,633
- Seema Harshit Savla
- 4.93%
- 4,567,514
- Harshit Manilal Savla
- 4.74%
- 4,390,733
- Rashesh Chandrakant Gogri
- 4.65%
- 4,305,016
- Priti Prakash Patil
- 4.4%
- 4,078,989
- Hetal Gogri Gala
- 3.06%
- 2,830,731
- Mirik Rajendra Gogri
- 2.16%
- 1,997,952
- Chandrakant Vallabhaji Gogri
- 1.88%
- 1,736,777
- Jaya Chandrakant Gogri
- 1.72%
- 1,588,422
- Renil Rajendra Gogri
- 1.65%
- 1,525,475
- Adhish P. Patil
- 1.23%
- 1,137,246
- Vishwa Harshit Savla
- 1.03%
- 954,571
- Aashay Rashesh Gogri
- 0.96%
- 889,558
- Rajendra Vallabhaji Gogri
- 0.84%
- 776,191
- Arti Rajendra Gogri
- 0.58%
- 537,157
- Jigna Hiren Shah
- 0.5%
- 459,633
- Jay Manilal Savla
- 0.32%
- 293,447
- Indira Madan Dedhia
- 0.23%
- 214,232
- Manisha Rashesh Gogri
- 0.2%
- 189,675
- Aarnav Rashesh Gogri
- 0.2%
- 189,273
- Arati Tushar Sankhe
- 0.19%
- 177,000
- Prakash M. Patil (HUF)
- 0.18%
- 164,078
- Arun Moreshwar Patil
- 0.08%
- 70,000
- Uday Moreshwar Patil
- 0.05%
- 50,922
- Vikas Moreshwar Patil
- 0.04%
- 34,675
- Kalika Amit Mishra
- 0.03%
- 25,556
- Kenisha Savla
- 0.01%
- 10,000
- Hriman Savla
- 0.01%
- 10,000
- Harshit M. Savla (HUF)
- 0.01%
- 5,956
- Gogri Finserv Pvt. Ltd.
- 3.8%
- 3,518,025
- Anushakti Enterprise Private Limited
- 2.62%
- 2,430,032
- Alchemie Finserv Pvt. Ltd.
- 2.21%
- 2,044,827
- Aashyav Business Trust
- 1.5%
- 1,389,783
- Safechem Enterprises Private Limited
- 1.32%
- 1,222,662
- Tulip Family Trust
- 1.01%
- 933,140
- Orchid Family Trust
- 0.99%
- 921,228
- Paridhi Business Trust
- 0.64%
- 595,622
- Dilesh Roadlines Pvt Ltd
- 0.54%
- 496,356
- Alchemie Financial Services Limited
- 0.04%
- 39,145
- Aarti Life Science LLP
- 0.01%
- 13,577
- Public Shareholding
- 40.23%
- 37,253,191
- Others
- 20.21%
- 18,717,701
- Nikhil Parimal Desai
- 1.17%
- 1,081,728
- Others
- 5.28%
- 4,891,356
- Harit Pragji Shah
- 2.67%
- 2,474,933
- Jayshree Harit Shah
- 1.79%
- 1,659,574
- Others
- 1%
- 922,347
- Dsp Small Cap Fund
- 3.05%
- 2,824,265
- Others
- 0.03%
- 30,774
- Others
- 1.94%
- 1,794,485
- HUF
- 0.7%
- 648,077
- Unclaimed or Suspense or Escrow Account
- 0.33%
- 302,027
- Bodies Corporate
- 0.07%
- 66,051
- Clearing Members
- 0.04%
- 38,620
- Others
- 0.72%
- 670,821
- Others
- 0.4%
- 369,841
- Others
- 0.36%
- 337,775
- Others
- 0.3%
- 281,970
- Others
- 0.08%
- 71,345
- Others
- 0.07%
- 68,000
- Others
- 0%
- 750
- Others
- 0%
- 615
- Others
- 0%
- 120
- Others
- 0%
- 16
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 20-Oct-22
- Quarterly Results
- 27-Jul-22
- Quarterly Results
- 09-May-22
- Audited Results
- 31-Jan-22
- Audited Results & Interim Dividend
- 27-Oct-21
- Quarterly Results
- 27-Jul-21
- Quarterly Results
- 15-May-21
- Audited Results
- 19-Mar-21
- Buy Back of Shares
- 25-Jan-21
- Quarterly Results
- Meeting Date
- Announced on
- Purpose
- 04-Sept-21
- 11-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 31-Jan-22
- 10-Feb-22
- 09-Feb-22
- 1
No recent bonus announcements.
No recent splits available.
No recent rights issue declared.
Company Profile
ABOUT Aarti Drugs
- Industry Biotechnology & Drugs
- ISIN INE767A01016
- BSE Code 524348
- NSE Code AARTIDRUGS
Aarti Drugs Limited is an India-based pharmaceutical company engaged in manufacturing active pharmaceutical ingredients (APIs), pharma intermediates, specialty chemicals. The Company, through its wholly-owned subsidiary Pinnacle Life Science Private Limited, is focused on producing formulations. The Company’s products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole and Ofloxacin. Its pharma intermediates products are Tinidazole, Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide and Raloxifene. It also offers specialty chemicals, such as Benzene Sulphonyl Chloride and Methyl Nicotinate. The Company’s products under development include Alcoholism Treatment, Anticoagulant, Antihyperphosphatemia, Anti-cholestrol, Cardiovascular, Cardiprotectant and Antidiabetic.
MANAGEMENT
- Prakash Patil Chairman of the Board, Chief Executive Officer, Managing Director, Executive Director
- Adhish Patil Chief Financial Officer
- Rushikesh Deole Compliance Officer, Company Secretary
- Harshit Savla Joint Managing Director, Executive Director
- Rashesh Gogri Managing Director, Executive Director
- Uday Patil Whole-Time Director
- Harit Pragji Shah Whole-Time Director
Company Summary
AARTI DRUGS SUMMARY
Aarti Drugs is trading 0.52% lower at Rs 458.55 as compared to its last closing price. Aarti Drugs has been trading in the price range of 461.5 & 453.0. Aarti Drugs has given -15.53% in this year & 2.08% in the last 5 days.
Aarti Drugs has TTM P/E ratio 23.19 as compared to the sector P/E of 27.15. There are 3 analysts who have initiated coverage on Aarti Drugs. There are 0 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.
The company posted a net profit of 38.74 Crores in its last quarter.
Listed peers of Aarti Drugs include FDC (-0.75%), Hikal (9.63%), Aarti Drugs (-0.52%) etc.
FAQs about Aarti Drugs
Aarti Drugs is trading at 458.55 as on 7 Dec, 2022 3:29:19 PM. This is -0.52% lower as compared to its previous closing price of 460.95
The market capitalization of Aarti Drugs is 4261.92 Cr as on 7 Dec, 2022 3:29:19 PM.
The average broker rating on Aarti Drugs is Hold. The breakup of analyst rating is given below -
- 0 analysts have given a strong sell rating
- 0 analysts have given a sell rating
- 2 analysts have given a hold rating
- 1 analysts have given a buy rating
- 0 analysts have given a strong buy rating
The 52 wk high for Aarti Drugs is 607.5 whereas the 52 wk low is 378.4
Aarti Drugs can be analyzed on the following key metrics -
- TTM P/E: 23.19
- Sector P/E: 27.15
- Dividend Yield: 0%
- D/E ratio: -
Aarti Drugs reported a net profit of 205.04 Cr in 2022.
